Released on: June 20, 2008, 8:24 am

Press Release Author: Belinda De Leon / Trevigen, Inc.

Industry: Biotech

Press Release Summary: Until now, commercially available PARP assay kits required
multiple steps and were time consuming. Trevigen overcomes these drawbacks with the
release of the HT Fluorescent Homogeneous PARP Inhibition Assay.

Press Release Body: Poly(ADP-ribose) polymerase, through ribosylation of nuclear
proteins, converts DNA Damage into intracellular signals that actuate either DNA
repair or cell death. The development of inhibitors to PARP is of ever increasing
interest in the drug discovery community since they can be used as modulators of DNA
repair mediated resistance to cytotoxic cancer therapeutics. Until now, commercially
available PARP assay kits required multiple steps and were time consuming.

Trevigen overcomes these drawbacks with the release of the HT Fluorescent
Homogeneous PARP Inhibition Assay. The fluorescent assay is based on the consumption
of NAD+ in the PARP ribosylation reaction where NAD+ not consumed by PARP is
subsequently measured by a cycling reaction in which a highly fluorescent molecule
is produced; therefore an increase in signal positively correlates to increased PARP
inhibition. The subject of a Trevigen patent application, it is a simple assay
requiring only 1.5 hours from start to finish. The 96 test assay requires no wash
steps, and detects as little as 10% inhibition ofPARP Activity. The assay is ideal
for the determination of IC50 values for PARP Inhibitors.

Trevigen, Inc. is a rapidly growing biotechnology company focused on the development
of products and technology for cancer research, emphasizing apoptosis, DNA damage
and repair, and cancer cell function and behavior. Trevigen has been a long-standing
provider of quality reagents and kits for researchers investigating programmed cell
death and DNA damage and repair. A logical extension of the focus on cancer research
has been the recent development of assays for cancer cell function and behavior
including angiogenesis, cell invasion and tumor formation. Currently, the product
portfolio contains over 500 products categorized into four processes - Apoptosis,
DNA Damage and Repair, Angiogenesis, and Oxidative Stress.

Related Products from Trevigen include PARP and PARG assay kits, PARP enzymes and
PARP antibodies. Visit www.trevigen.com or contact us at 1800-873-8443 or
info@trevigen.com for more information.


Web Site: http://www.trevigen.com

Contact Details: Trevigen, Inc.
8405 Helgerman Court
Gaitherburg, MD 20877
www.trevigen.com
info@trevigen.com
1.800.873.8443